Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in pediatric moderately to severely active ulcerative colitis
2025-523100-77-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of etrasimod in autoimmune colitis, sponsored by Pfizer. Primary endpoint: Clinical remission based on modified Mayo score at Week 52. Planned start Apr 2026; status: authorised.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-523100-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523100-77-00.